RECRUITINGOBSERVATIONAL
Mi-RNA and COVID-19
Circulating Mi-RNA Associated With Disease Severity and Outcome in COVID-19 Patients
About This Trial
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease, characterized by respiratory failure, shock and multi-organ dysfunction requiring admission in the intensive care unit (ICU). The aim of the present study is to analyze miRNAs associated with SARS-CoV-2 infection, disease severity and mortality.
Who May Be Eligible (Plain English)
Who May Qualify:
- 18 years
- diagnosis of SARS-CoV-2 infection confirmed by molecular testing on nasopharyngeal swabs
Who Should NOT Join This Trial:
- pregnant women
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* 18 years
* diagnosis of SARS-CoV-2 infection confirmed by molecular testing on nasopharyngeal swabs
Exclusion Criteria:
* pregnant women
Treatments Being Tested
DIAGNOSTIC_TEST
mi-RNA analysis
To identify biomarkers that could predict the risk of a worsened COVID-19 disease progression.
Locations (1)
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, RM, Italy